Cohort | Patient | Age/sex | Total cells infused(×10−9) | CD4/CD8(%) | VB12(%) | MART-1 cells infused(×10−9)‡ | Days in culture | Doubling time(days)† | IL-2 doses § | Sites of evaluable disease | Response(duration in months)|| |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 1 | 28/M | 11.0 | 27/73 | 67 | 7.4 | 19 | 8.7 | 7 | Ln, Cu | NR |
2a* | 44/F | 13.0 | 3/95 | 64 | 8.3 | 19 | 11.9 | 10 | Ln, Cu | NR | |
3 | 58/M | 14.0 | 17/82 | 35 | 4.9 | 19 | 10.0 | 11 | Cu, Sub | NR | |
2 | 4 | 52/M | 1.0 | 50/50 | 42 | 0.5 | 6 | 1.4 | 9 | Li, Sub | PR(21) |
5 | 50/M | 12.0 | 18/82 | 17 | 2.2 | 8 | 1.0 | 7 | Lu, Ln, Sub | NR | |
6 | 55/F | 7.0 | 37/72 | 51 | 3.6 | 7 | 1.3 | 8 | Lu, Ln | NR | |
7 | 56/M | 9.0 | 75/21 | 40 | 3.6 | 7 | 1.0 | 5 | Lu, Ln | NR | |
8 | 37/M | 6.1 | 68/40 | 32 | 1.9 | 7 | 1.3 | 12 | Lu, Ln | NR | |
9 | 53/M | 4.2 | 72/24 | 41 | 1.7 | 7 | 2.0 | 9 | Ln, Ad, Sub | MR | |
10 | 45/M | 8.6 | 53/30 | 34 | 2.9 | 6 | 0.6 | 5 | Ln, Sub | ||
11 | 45/M | 6.3 | 7/92 | 45 | 2.8 | 6 | 0.8 | 5 | Lu, Pa, Ln | NR | |
12 | 32/F | 4.7 | 30/60 | 61 | 2.9 | 6 | 0.7 | 5 | Br, Sub | NR | |
13 | 41/M | 7.7 | 40/67 | 42 | 3.2 | 6 | 0.9 | 7 | Lu, Sub | NR | |
2b* | 44/F | 2.1 | 30/59 | 53 | 1.1 | 6 | 1.9 | 14 | Ln, Cu | NR | |
3 | 14 | 30/M | 86 | 11/60 | 40 | 34.4 | 18+9 | 0.9 | 5 | Hi | PR(20) |
15 | 51/M | 38 | 16/82 | 45 | 17.1 | 18+9 | 3.3 | 8 | Lu | NR | |
16 | 25/F | 33 | 13/76 | 21 | 6.9 | 18+9 | 1.2 | 2 | Lu, Li, Sub | NR | |
17 | 20/F | 23 | 17/78 | 30 | 6.9 | 17+8 | 1.1 | 3 | Lu, Ln, Sub | NR |